Key result
Empagliflozin linked to ~82% lower risk of CTRCD during anthracycline chemotherapy for breast cancer.
Why the study?
Does empagliflozin reduce the incidence of cancer therapy-related cardiac dysfunction in high-risk breast cancer patients undergoing anthracycline-based chemotherapy?
Population
High-risk patients treated with anthracyclines
Authors
Loading...
Empagliflozin was associated with lower CTRCD risk; leaves open a protective effect pending randomized confirmation.
Case-Control (n=76)
Open-label
No
Does empagliflozin reduce the incidence of cancer therapy-related cardiac dysfunction in high-risk breast cancer patients undergoing anthracycline-based chemotherapy?
Relative Risk: 0.18 (95% CI 0.04–0.75)
Absolute Event Rate: 6.5% vs 35.5%
p-value: p=0.005
Empagliflozin significantly reduced the incidence of cancer therapy-related cardiac dysfunction and preserved ejection fraction in high-risk breast cancer patients receiving anthracycline chemotherapy.
Daniele et al. (2024) conducted a case-control in Breast cancer at high risk of anthracycline-induced cardiotoxicity (n=76). Empagliflozin vs. Control was evaluated on Cancer therapy-related cardiac dysfunction (CTRCD) incidence (RR 0.18, 95% CI 0.04-0.75, p=0.005). Empagliflozin significantly reduced the incidence of cancer therapy-related cardiac dysfunction compared to control (6.5% vs. 35.5%, RR 0.18) in high-risk breast cancer patients receiving anthracyclines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: